15928302	472	Thompson D	Cancer risks and mortality in heterozygous ATM mutation carriers.	Journal of the National Cancer Institute	2005	85
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
10433620	675	Breast Cancer Linkage Consortium.	Cancer risks in BRCA2 mutation carriers.	Journal of the National Cancer Institute	1999	251
8033105	999	Becker KF	E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.	Cancer research	1994	139
17545690	999	Kaurah P	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.	JAMA	2007	66
20591882	999	Fitzgerald RC	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.	Journal of medical genetics	2010	71
23341533	999	Corso G	Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer.	Journal of clinical oncology 	2013	28
25979631	999	van der Post RS	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.	Journal of medical genetics	2015	26
22104201	1045	Jang BG	Molecular pathology of gastric carcinoma.	Pathobiology 	2011	41
26182300	1495	Hansford S	Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.	JAMA oncology	2015	23
15613856	1674	Miettinen M	Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.	The American journal of surgical pathology	2005	174
21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
10223227	2064	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	113
16868827	2064	Park DI	HER-2/neu amplification is an independent prognostic factor in gastric cancer.	Digestive diseases and sciences	2006	70
19156142	2064	Barros-Silva JD	Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.	British journal of cancer	2009	50
24127447	2064	Gomez-Martin C	Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.	Journal of clinical oncology 	2013	32
26628478	2064	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	58
23680147	2065	Jaiswal BS	Oncogenic ERBB3 mutations in human cancers.	Cancer cell	2013	69
22240789	2263	Matsumoto K	FGFR2 gene amplification and clinicopathological features in gastric cancer.	British journal of cancer	2012	30
23493349	2263	Xie L	FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.	Clinical cancer research 	2013	49
8598045	2272	Ohta M	The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.	Cell	1996	207
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
27496117	2956	Provenzale D	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.	Journal of the National Comprehensive Cancer Network 	2016	15
7729872	3576	Sharma SA	Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro.	Infection and immunity	1995	115
20548334	3717	Ding L	MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.	Cell research	2010	86
11213830	3815	Miettinen M	Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.	Virchows Archiv 	2001	241
17090188	3815	Miettinen M	Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.	Archives of pathology and laboratory medicine	2006	262
18076015	3815	Dematteo RP	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).	Cancer	2008	96
27011036	3815	Boikos SA	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.	JAMA oncology	2016	15
20841479	3845	Cepero V	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.	Cancer research	2010	46
21424128	4233	Lee J	Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.	Oncology reports	2011	42
18398828	4292	Watson P	The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.	International journal of cancer	2008	95
23623056	5156	Joensuu H	Gastrointestinal stromal tumour.	Lancet	2013	55
15016963	5290	Samuels Y	High frequency of mutations of the PIK3CA gene in human cancers.	Science	2004	909
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
25894828	7157	Cristescu R	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.	Nature medicine	2015	84
21415212	10562	Oh HK	Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer.	Clinical cancer research 	2011	65
17909001	55294	Akhoondi S	FBXW7/hCDC4 is a general tumor suppressor in human cancer.	Cancer research	2007	139
